Torti's Next Hundred Days: Active, Not Just Acting FDA Commissoner
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Chief Scientist will continue to push for outside academic collaborations during his "short time" atop the agency; fall letter on follow-on biologics could draw closer reading.
You may also be interested in...
Waxman-Hatch Generic Drug Law Architect Returns To HHS As Daschle’s Deputy
Bill Corr was one of the architects of the ANDA/patent restoration deal behind the Waxman/Hatch legislation in 1984 - and, a quarter century later, is well positioned to make sure follow-on biologics find a place in health reform.
FDA’s Torti Tapped As Acting Commissioner; Interim Heads Also Named For HHS, CMS
Chief scientist Frank Torti is a relative newcomer to FDA, having joined less than a year ago from Wake Forest University. Since then, he has headed the agency’s successful fellowship program.
Heads Of FDA, CMS And Other HHS Agencies May Be Named Within A Few Weeks
HHS Secretary-nominee Tom Daschle tells Senate HELP Committee there needs to be better coordination within the department.